PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Announces Symmetric & Asymmetric Dimethylated Arginine in Histone Peptides Collection - AnaSpec, EGT Group offers one of the world’s largest selections of Histone GO® (catalog) peptides - Anaspec.com / Eurogentec.com
AnaSpec Announces Symmetric & Asymmetric Dimethylated Arginine in Histone Peptides Collection

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/02/13 - AnaSpec, EGT Group offers one of the world’s largest selections of Histone GO® (catalog) peptides - Anaspec.com / Eurogentec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Our peptides include sequences containing modified amino acids such as methylated (Me1, Me2 and Me3) Lysine; phosphorylated Threonine (pThr) or Serine (pSer); deiminated Arginine (Cit). We also offer symmetric and asymmetric dimethylated Arginine (Me2s and Me2a) in addition to monomethylated Arginine (Me1).
Methylation of arginine residues are mediated by members of the protein arginine methyltransferases (PRMTs) family. PRMT type I adds asymmetrically dimethyl groups to arginine (ADMA), while type II add symmetrically dimethyl groups (SDMA). Type III adds monomethyl group to arginine.1 Type 1 PRMT, Coactivator-associated arginine methyltransferase 1 (CARM1), also known as PRMT4, methylates Histone 3 at R2, R17 and R26. CARM1 methylation of H3R17 activates transcription.2-4 PRMT5, which catalyzes H3R8 and H4R3 symmetric dimethylation leads to repression of gene expression, while PRMT1 asymmetric dimethylation of H4R3 is associated with gene activation.4, 5
AnaSpec, EGT Group is the sole provider of the industry’s long wavelength HDAC assay kit, the SensoLyte 520 HDAC Activity Assay Kit. We also provide unusual amino acid building blocks such as Lys(Ac), Lys(Me1-3), Arg(Me2), pSer and pThr for histone peptide synthesis.

Reference:
1. Bedford MT, et al. Mol Cell 18, 263 (2005).
2. Chen, D. et al. Science 284, 2174 (1999).
3. Ma, H. et al. Curr Biol 11, 1981 (2001).
4. Schurter, BT. et al. Biochem 40, 5747 (2001).
5. Pal, S. et al. Mol Cell Biol 24, 9630 (2004).

AnaSpec, Eurogentec Group

AnaSpec, Eurogentec Group (anaspec.com) is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Announces Symmetric & Asymmetric Dimethylated Arginine in Histone Peptides Collection

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)